Amgen, SoftBank and Alexandria Real Estate Equities helped the neurodegenerative disease drug developer publicly launch with $500m in funding.
Neumora Therapeutics, a US-based developer of brain disease treatments, has collected over $500m in a series A round that included $100m from pharmaceutical firm Amgen.
Internet and telecommunications conglomerate SoftBank’s Vision Fund 2 also took part in the round, as did life sciences real estate investment trust Alexandria Real Estate Equities, through venture capital arm Alexandria Venture Investments.
The round was led by Arch Venture Partners and also backed by investment and financial services group Fidelity’s F-Prime Capital unit, Altitude…
